India Rifampicin Market to grow at a steady rate During the Forecast Period
High prevalence of
tuberculosis is expected to drive the growth of India Rifampicin market.
According
to TechSci Research report, “India Rifampicin Market By Source (In-house v/s
Contract Manufacturing Organizations), By Form (Tablet, Capsule and Injection),
By Route of Administration (Oral v/s Intravenous), By Distribution Channel
(Online v/s Offline), By Application (Tuberculosis, Leprosy, Legionnaire's
Disease and Others), By End User (Adult v/s Paediatric), By Company, By Region,
Forecast & Opportunities, FY2026”, the India rifampicin market is expected to grow at a
steady rate during the forecast period for the treatment of tuberculosis. Rifampicin
is an effective antibiotic against gram-positive bacteria such as mycobacteria.
Therefore, it is being frequently used in the treatment of tuberculosis along
with isoniazid, pyrazinamide and ethambutol/streptomycin. In addition to this, rifampicin
is used alone in patients with latent tuberculosis infections to prevent or
prolong the development of active disease which is expected to fuel the market
growth through FY2026. However, side-effects associated with drug consumption
such as temporary discoloration of your skin, teeth, saliva, urine, stool,
sweat, and tears, itching, flushing, headache, drowsiness, dizziness, lack of
coordination can restrict the market growth over the next few years. Moreover, increasing
incidence of drug recall can further reduce the usage and application of the
drug thereby hindering the market growth during the forecast period.
Browse
XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC
on "India Rifampicin Market"
https://www.techsciresearch.com/report/india-rifampicin-market/7231.html
The India rifampicin market is segmented based on source, form, route of
administration, distribution channel, application, end user, company, and
region. Based on route of administration, the market can be fragmented into oral
v/s intravenous. The oral route of administration segment is expected to
dominate the market in the forthcoming years on account of its versatility to
accommodate various types of drugs. Moreover, the oral route is the most
convenient and usually the safest, thereby positively influencing the segmental
growth in the upcoming years. Based on source, the market can be categorized
into in-house v/s contract manufacturing organizations. The in-house segment
dominated the market until 2019 as most of the leading companies focus on in
house production. Contract manufacturing organizations segment is expected to
witness significant growth in the market as it saves cost and maximize profits.
Besides, high growth in number of contract manufacturers is further
contributing to its fast growing CAGR. In terms of form, the market is split
into tablet, capsule, and injection. Among them, the capsule segment is
anticipated to register high growth in the market over the next 5 years which
is attributable to the fact that they are easy to use, readily available and tend
to break down more quickly than tablets.
Indian Drugs and Pharmaceuticals
Ltd., Cadila Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Lupin
Laboratories Ltd., Concept Pharmaceuticals Ltd., Novartis India Ltd., Zydus
Cadila Healthcare Ltd., Themis Pharmaceuticals Ltd., GlaxoSmithKline
Pharmaceuticals Ltd, Taurus Laboratories
Pvt. Ltd. and others are some of the leading players operating
in India rifampicin market. Companies operating in the market are using Go-to-Market
strategies such as product launches, mergers and acquisitions and research collaborations
to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7231
Customers can also request for 10% free
customization on this report.
“India rifampicin market is expected to
witness growth during the forecast period as it is used to treat patients with
tuberculosis. It is estimated that about 40% of the Indian population is
infected with TB bacteria. Additionally, major market players are focusing on
strategic collaborations to commercialize their newly developed drugs. This is
further expected to create lucrative opportunities for the market growth of India
rifampicin market over the next five years.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research based India
management consulting firm.
“India Rifampicin Market By Source (In-house v/s
Contract Manufacturing Organizations), By Form (Tablet, Capsule and Injection),
By Route of Administration (Oral v/s Intravenous), By Distribution Channel
(Online v/s Offline), By Application (Tuberculosis, Leprosy, Legionnaire's
Disease and Others), By End User (Adult v/s Paediatric), By Company, By Region,
Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India rifampicin
market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in India rifampicin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]